Drugs / DEFERITAZOLE
DEFERITAZOLE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01905540 | Aug → Sep 2013 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01824446 | May 2013 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01732263 | Nov 2012 → Apr 2013 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01716455 | Oct 2012 → Mar 2013 | impaired renal function disease | Shire | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DEFERITAZOLE | ChEMBL registry synonym — accepted as the source's own label CHEMBL487465 ↗ |
| Known as | Deferitazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL487465 ↗ |
| Known as | FBS0701 | “Radiolabeled SPD602 (FBS0701, SSP-004184)” NCT01824446 ↗ |
| Known as | Fbs0701, spd602 | ChEMBL registry synonym — accepted as the source's own label CHEMBL487465 ↗ |
| Known as | SPD-602 | ChEMBL registry synonym — accepted as the source's own label CHEMBL487465 ↗ |
| Known as | SSP-004184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01824446 ↗ |
| Modality | Small molecule | — CHEMBL487465 ↗ |
| Route | Oral | “75 mg/kg, oral capsule” NCT01716455 ↗ |